Last updated: April 15, 2024
Sponsor: Shandong Provincial Hospital
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Non-ulcer Dyspepsia (Nud)
Heartburn
Bowel Dysfunction
Treatment
Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
Mononuclear cells
Clinical Study ID
NCT05808010
SWYX:NO.2022-1037
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Subjects voluntarily participated in the study and signed an informed consent.
- The age is 18-65 years old, regardless of gender.
- Patients with chronic atrophic gastritis by gastroscopy and pathological examination.
- Patients with a negative C13 breath test or have eradicated Helicobacter pyloriinfection.
- Patients without contraindications to submucosal injection of umbilical cord bloodderived mononuclear cells.
Exclusion
Exclusion Criteria:
- Patients with gastric ulcer, erosive gastritis, active upper gastrointestinalbleeding, gastric varices, or other gastric tumors.
- Patients who are taking or have taken proton pump inhibitors, antibiotics,glucocorticoids, nonsteroidal anti-inflammatory drugs and immunosuppressants in thelast six months.
- People who have had gastric surgery or required gastric surgery during the study.
- Patients with severe systemic diseases (diseases of cardiovascular, liver, blood,kidneys, lungs or liver).
- Pregnant or nursing females.
- Patients who are reluctant to accept endoscopy and treatment.
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
Phase:
Study Start date:
June 07, 2023
Estimated Completion Date:
April 30, 2026
Connect with a study center
Shandong Provincial Hospital
Jinan, Shandong 250021
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.